Neuropsychopharmacology of JNJ-55308942

evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia

Anindya Bhattacharya, Brian Lord, Jan Sebastian Grigoleit, Yingbo He, Ian Fraser, Shannon N. Campbell, Natalie Taylor, Leah Aluisio, Jason O'connor, Mariusz Papp, Christa Chrovian, Nicholas Carruthers, Timothy W. Lovenberg, Michael A. Letavic

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Emerging data continues to point towards a relationship between neuroinflammation and neuropsychiatric disorders. ATP-induced activation of P2X7 results in IL-1β release causing neuroinflammation and microglial activation. This study describes the in-vitro and in-vivo neuropharmacology of a novel brain-penetrant P2X7 antagonist, JNJ-55308942, currently in clinical development. JNJ-55308942 is a high-affinity, selective, brain-penetrant (brain/plasma of 1) P2X7 functional antagonist. In human blood and in mouse blood and microglia, JNJ-55308942 attenuated IL-1β release in a potent and concentration-dependent manner. After oral dosing, the compound exhibited both dose and concentration-dependent occupancy of rat brain P2X7 with an ED50 of 0.07 mg/kg. The P2X7 antagonist (3 mg/kg, oral) blocked Bz-ATP-induced brain IL-1β release in conscious rats, demonstrating functional effects of target engagement in the brain. JNJ-55308942 (30 mg/kg, oral) attenuated LPS-induced microglial activation in mice, assessed at day 2 after a single systemic LPS injection (0.8 mg/kg, i.p.), suggesting a role for P2X7 in microglial activation. In a model of BCG-induced depression, JNJ-55308942 dosed orally (30 mg/kg), reversed the BCG-induced deficits of sucrose preference and social interaction, indicating for the first time a role of P2X7 in the BCG model of depression, probably due to the neuroinflammatory component induced by BCG inoculation. Finally, in a rat model of chronic stress induced sucrose intake deficit, JNJ-55308942 reversed the deficit with concurrent high P2X7 brain occupancy as measured by autoradiography. This body of data demonstrates that JNJ-55308942 is a potent P2X7 antagonist, engages the target in brain, modulates IL-1β release and microglial activation leading to efficacy in two models of anhedonia in rodents.

Original languageEnglish (US)
JournalNeuropsychopharmacology
DOIs
StateAccepted/In press - Jan 1 2018
Externally publishedYes

Fingerprint

Anhedonia
Ion Channels
Animal Models
Brain
Mycobacterium bovis
Interleukin-1
Sucrose
Neuropharmacology
Depression
Microglia
Interpersonal Relations
Autoradiography
Rodentia
Adenosine Triphosphate
Injections

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health

Cite this

Neuropsychopharmacology of JNJ-55308942 : evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia. / Bhattacharya, Anindya; Lord, Brian; Grigoleit, Jan Sebastian; He, Yingbo; Fraser, Ian; Campbell, Shannon N.; Taylor, Natalie; Aluisio, Leah; O'connor, Jason; Papp, Mariusz; Chrovian, Christa; Carruthers, Nicholas; Lovenberg, Timothy W.; Letavic, Michael A.

In: Neuropsychopharmacology, 01.01.2018.

Research output: Contribution to journalArticle

Bhattacharya, A, Lord, B, Grigoleit, JS, He, Y, Fraser, I, Campbell, SN, Taylor, N, Aluisio, L, O'connor, J, Papp, M, Chrovian, C, Carruthers, N, Lovenberg, TW & Letavic, MA 2018, 'Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia', Neuropsychopharmacology. https://doi.org/10.1038/s41386-018-0141-6
Bhattacharya, Anindya ; Lord, Brian ; Grigoleit, Jan Sebastian ; He, Yingbo ; Fraser, Ian ; Campbell, Shannon N. ; Taylor, Natalie ; Aluisio, Leah ; O'connor, Jason ; Papp, Mariusz ; Chrovian, Christa ; Carruthers, Nicholas ; Lovenberg, Timothy W. ; Letavic, Michael A. / Neuropsychopharmacology of JNJ-55308942 : evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia. In: Neuropsychopharmacology. 2018.
@article{37020af5713f4fbab675bf6ee75800cb,
title = "Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia",
abstract = "Emerging data continues to point towards a relationship between neuroinflammation and neuropsychiatric disorders. ATP-induced activation of P2X7 results in IL-1β release causing neuroinflammation and microglial activation. This study describes the in-vitro and in-vivo neuropharmacology of a novel brain-penetrant P2X7 antagonist, JNJ-55308942, currently in clinical development. JNJ-55308942 is a high-affinity, selective, brain-penetrant (brain/plasma of 1) P2X7 functional antagonist. In human blood and in mouse blood and microglia, JNJ-55308942 attenuated IL-1β release in a potent and concentration-dependent manner. After oral dosing, the compound exhibited both dose and concentration-dependent occupancy of rat brain P2X7 with an ED50 of 0.07 mg/kg. The P2X7 antagonist (3 mg/kg, oral) blocked Bz-ATP-induced brain IL-1β release in conscious rats, demonstrating functional effects of target engagement in the brain. JNJ-55308942 (30 mg/kg, oral) attenuated LPS-induced microglial activation in mice, assessed at day 2 after a single systemic LPS injection (0.8 mg/kg, i.p.), suggesting a role for P2X7 in microglial activation. In a model of BCG-induced depression, JNJ-55308942 dosed orally (30 mg/kg), reversed the BCG-induced deficits of sucrose preference and social interaction, indicating for the first time a role of P2X7 in the BCG model of depression, probably due to the neuroinflammatory component induced by BCG inoculation. Finally, in a rat model of chronic stress induced sucrose intake deficit, JNJ-55308942 reversed the deficit with concurrent high P2X7 brain occupancy as measured by autoradiography. This body of data demonstrates that JNJ-55308942 is a potent P2X7 antagonist, engages the target in brain, modulates IL-1β release and microglial activation leading to efficacy in two models of anhedonia in rodents.",
author = "Anindya Bhattacharya and Brian Lord and Grigoleit, {Jan Sebastian} and Yingbo He and Ian Fraser and Campbell, {Shannon N.} and Natalie Taylor and Leah Aluisio and Jason O'connor and Mariusz Papp and Christa Chrovian and Nicholas Carruthers and Lovenberg, {Timothy W.} and Letavic, {Michael A.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1038/s41386-018-0141-6",
language = "English (US)",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Neuropsychopharmacology of JNJ-55308942

T2 - evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia

AU - Bhattacharya, Anindya

AU - Lord, Brian

AU - Grigoleit, Jan Sebastian

AU - He, Yingbo

AU - Fraser, Ian

AU - Campbell, Shannon N.

AU - Taylor, Natalie

AU - Aluisio, Leah

AU - O'connor, Jason

AU - Papp, Mariusz

AU - Chrovian, Christa

AU - Carruthers, Nicholas

AU - Lovenberg, Timothy W.

AU - Letavic, Michael A.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Emerging data continues to point towards a relationship between neuroinflammation and neuropsychiatric disorders. ATP-induced activation of P2X7 results in IL-1β release causing neuroinflammation and microglial activation. This study describes the in-vitro and in-vivo neuropharmacology of a novel brain-penetrant P2X7 antagonist, JNJ-55308942, currently in clinical development. JNJ-55308942 is a high-affinity, selective, brain-penetrant (brain/plasma of 1) P2X7 functional antagonist. In human blood and in mouse blood and microglia, JNJ-55308942 attenuated IL-1β release in a potent and concentration-dependent manner. After oral dosing, the compound exhibited both dose and concentration-dependent occupancy of rat brain P2X7 with an ED50 of 0.07 mg/kg. The P2X7 antagonist (3 mg/kg, oral) blocked Bz-ATP-induced brain IL-1β release in conscious rats, demonstrating functional effects of target engagement in the brain. JNJ-55308942 (30 mg/kg, oral) attenuated LPS-induced microglial activation in mice, assessed at day 2 after a single systemic LPS injection (0.8 mg/kg, i.p.), suggesting a role for P2X7 in microglial activation. In a model of BCG-induced depression, JNJ-55308942 dosed orally (30 mg/kg), reversed the BCG-induced deficits of sucrose preference and social interaction, indicating for the first time a role of P2X7 in the BCG model of depression, probably due to the neuroinflammatory component induced by BCG inoculation. Finally, in a rat model of chronic stress induced sucrose intake deficit, JNJ-55308942 reversed the deficit with concurrent high P2X7 brain occupancy as measured by autoradiography. This body of data demonstrates that JNJ-55308942 is a potent P2X7 antagonist, engages the target in brain, modulates IL-1β release and microglial activation leading to efficacy in two models of anhedonia in rodents.

AB - Emerging data continues to point towards a relationship between neuroinflammation and neuropsychiatric disorders. ATP-induced activation of P2X7 results in IL-1β release causing neuroinflammation and microglial activation. This study describes the in-vitro and in-vivo neuropharmacology of a novel brain-penetrant P2X7 antagonist, JNJ-55308942, currently in clinical development. JNJ-55308942 is a high-affinity, selective, brain-penetrant (brain/plasma of 1) P2X7 functional antagonist. In human blood and in mouse blood and microglia, JNJ-55308942 attenuated IL-1β release in a potent and concentration-dependent manner. After oral dosing, the compound exhibited both dose and concentration-dependent occupancy of rat brain P2X7 with an ED50 of 0.07 mg/kg. The P2X7 antagonist (3 mg/kg, oral) blocked Bz-ATP-induced brain IL-1β release in conscious rats, demonstrating functional effects of target engagement in the brain. JNJ-55308942 (30 mg/kg, oral) attenuated LPS-induced microglial activation in mice, assessed at day 2 after a single systemic LPS injection (0.8 mg/kg, i.p.), suggesting a role for P2X7 in microglial activation. In a model of BCG-induced depression, JNJ-55308942 dosed orally (30 mg/kg), reversed the BCG-induced deficits of sucrose preference and social interaction, indicating for the first time a role of P2X7 in the BCG model of depression, probably due to the neuroinflammatory component induced by BCG inoculation. Finally, in a rat model of chronic stress induced sucrose intake deficit, JNJ-55308942 reversed the deficit with concurrent high P2X7 brain occupancy as measured by autoradiography. This body of data demonstrates that JNJ-55308942 is a potent P2X7 antagonist, engages the target in brain, modulates IL-1β release and microglial activation leading to efficacy in two models of anhedonia in rodents.

UR - http://www.scopus.com/inward/record.url?scp=85050274679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050274679&partnerID=8YFLogxK

U2 - 10.1038/s41386-018-0141-6

DO - 10.1038/s41386-018-0141-6

M3 - Article

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

ER -